Astrocytoma
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
Subtype terms (1)
More specific conditions that are subtypes of Astrocytoma in the MeSH hierarchy.
- Glioblastoma
709 drugs (241 approved, 468 experimental)
Drugs by status
Approved for this indication (5)
Phase 4 trials (2)
Phase 3 trials (19)
Phase 2 trials (89)
- mannitol
- 131i-tm-601
- fluorothymidine
- mercaptopurine
- aglatimagene besadenovec
- aminolevulinic acid
- atezolizumab
- antineoplaston a10
- antineoplaston AS2-1
- atengenal
- bendamustine
- binimetinib
- bmx-001
- boronophenylalanine
- irinotecan
- lenalidomide
- temsirolimus
- cilengitide
- selinexor
- doxorubicin
- ds-1001b
- encorafenib
- etirinotecan pegol
- olutasidenib
- g207
- paclitaxel
- lapatinib
- nintedanib
- aldesleukin
- ritonavir
- +59 more
Phase 1 trials (104)
- fingolimod
- phenobarbital
- azacitidine
- plerixafor
- amg 595
- apx005m
- mk-1775
- azd-8055
- azurin-derived cell-penetrating peptide p28
- urea
- sorafenib
- procaine benzylpenicillin
- carboxylesterase-expressing allogeneic neural stem cells
- carcinoembryonic antigen-expressing measles virus
- cb-839
- tadalafil
- cudc-907
- dec-205/ny-eso-1 fusion protein cdx-1401
- e. coli cd-expressing genetically modified neural stem cells
- ef5
- fluorodopa
- fosphenytoin
- gemcitabine
- ima950
- imiquimod
- carbamazepine
- incb7839
- Filgrastim
- inxn-2001
- ispinesib
- +74 more
Other trials (15)
- 18f-fluoro-dihydroxyphenylalanine
- bafetinib
- bone autograft
- busulfan
- etanidazole
- gadobutrol
- ga 68-edotreotide
- genetically-modified neural stem cells expressing e.coli cytosine deaminase
- mab-425
- fluorescein
- hepatitis a vaccine, inactivated
- inactivated influenza vaccine
- gadobenate
- tetanus toxoid
- autologous hematopoietic stem cells
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (39)
- Merck
- Hannover Clinical Trial Center GmbH
- Isarna Therapeutics GmbH
- Northwest Biotherapeutics
- Orbus Therapeutics, Inc.
- Shandong Lanjin Pharmaceuticals Co.,Ltd
- Tocagen Inc.
- Colombian Foundation for Epilepsy and Neurological Disease
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
- German Cancer Research Center
- Mashhad University of Medical Sciences
- Neuro-Oncology Working Group of the German Cancer Society
- NRG Oncology
- North Central Cancer Treatment Group
- Radiation Therapy Oncology Group
- Sichuan University
- University of Heidelberg
- University of Rochester
- University of Bonn
- University of Zurich
- University of Leipzig
- Mayo Clinic
- Capital Medical University
- Fudan University
- University of California, Los Angeles
- University of California, San Francisco
- Tianjin Medical University
- Sun Yat-Sen University
- Colombian foundation center for epilepsy and neurological disease
- +9 more
Organization Involved with Phase 2 Indications (78)
- Candel Therapeutics
- Exelixis
- Genentech
- MediGene
- Pfizer
- AEterna Zentaris
- Sugen
- Array BioPharma
- Axelar AB
- Bayer
- AOI Pharmaceuticals, Inc.
- Light Sciences Oncology
- Medicenna Therapeutics, Inc.
- Monteris Medical
- Nektar Therapeutics
- Oblato, Inc.
- Avid Bioservices
- Sponsor GmbH
- Teva
- TransMolecular
- Boehringer Ingelheim
- Boneca Corporation
- TVAX Biomedical
- National Institutes of Health (NIH)
- National Cancer Center, Korea
- Maastricht University
- University of Pittsburgh
- Baylor University
- Burzynski Research Institute
- Case Western Reserve University
- +48 more
Organization Involved with Phase 1 Indications (57)
- Celgene
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Amgen
- Pharmacyclics
- Curis
- Genzyme
- Sanofi
- Biogen
- GlaxoSmithKline
- Oncovir, Inc.
- Oncoceutics, Inc.
- Apexigen, Inc.
- Vanquish Oncology, Inc.
- London Vaccination Clinic
- Xenova Biomedix
- University of Pennsylvania
- Cancer and Leukemia Group B (CALGB)
- Providence Health & Services
- Thomas Jefferson University
- University of Miami
- University of Nebraska
- University of Toronto
- Stony Brook University
- University of Minnesota
- Hofstra University
- Institut de Cancerologie de l'Ouest Paul Papin
- University of Lille
- European Organisation for Research and Treatment of Cancer
- City of Hope National Medical Center
- +27 more
Organization Involved with Other Experimental Indications (8)